Tag: Macular Degeneration
Age-Related Macular Degeneration Prevalence Remains High
1.49 million people aged 40 years and older are living with late-stage AMD in the United States
AAO: One in Nine Patients With Wet AMD Skip Follow-Up
Odds of being lost to follow-up greater among very old patients, Black and Hispanic patients, and Medicaid patients
Pathways to Advanced Age-Related Macular Degeneration Examined
Distinct serum and genetic risks, associated systemic diseases seen with soft drusen, subretinal drusenoid deposits
Cost of Ranibizumab Port Delivery System for Treating nAMD Examined
Model compares costs for ranibizumab port delivery system versus conventional intravitreal antivascular endothelial growth factor injections
Lutein/Zeaxanthin in AREDS2 May Slow Progression to Late AMD
No increased risk for lung cancer, reduced risk for progression to late AMD seen with lutein/zeaxanthin as replacement for beta-carotene
Odds of Prior Migraine Up for Patients With Neovascular AMD
Odds of prior migraine increased for those with neovascular AMD versus propensity score-matched controls
Trials Show Promise for Intravitreal Faricimab in Retinal Disease
Faricimab noninferior to aflibercept for visual acuity gains in neovascular age-related macular degeneration, diabetic macular edema
Aqueous Biomarkers May Help Predict Treatment Response in nvAMD
Treated patients who required less frequent anti-VEGF injections had increased apolipoprotein B100
Smoking, Alcohol Intake Tied to Age-Related Macular Degeneration
Findings based on mendelian randomization for genetically predicted smoking initiation, alcohol intake
First Biosimilar Approved for Macular Degeneration, Other Eye Conditions
Biosimilar to Lucentis approved to treat neovascular age-related macular degeneration, macular edema, myopic choroidal neovascularization
